Sen. Ron Wyden (D-Ore.) on Wednesday called for further details on an agreement between Pfizer and President Trump to defer the drugmaker’s planned price increases.
On Tuesday, Pfizer announced that it would delay previously-announced plans to hike the price of 41 drugs, which were the topic of a critical tweet by Trump. The company said the prices will remain at the pre-increase levels until either the end of the year or the implementation of a White House drug pricing plan.
Wyden said the agreement does not go far enough to ensure lasting price reductions. He noted that other companies have announced price increases and he asked HHS Secretary Alex Azar if similar arrangements would be made with those companies.